Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ontamalimab
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Ontamalimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody that targets mucosal addressin cell adhesion molecule 1 (MAdCAM1). It was developed as a novel treatment for inflammatory bowel diseases by inhibiting the interaction between MAdCAM1 and its ligand α4β7 integrin, thereby reducing lymphocyte trafficking to the gut and modulating intestinal inflammation. Ontamalimab was primarily investigated for moderate to severe Crohn's disease and ulcerative colitis. The drug demonstrated efficacy in inducing and maintaining clinical remission in these conditions but its development program for inflammatory bowel diseases was discontinued by the sponsor for reasons unrelated to safety or efficacy. It has also been studied at an earlier stage for non-alcoholic steatohepatitis[5][6][7].
- Brand names
- ontamalimab
- Other names
- human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule MAdCAMhuman IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule
02
Targets
MADCAM1 (Mucosal addressin cell adhesion molecule 1)
Beyond the preview
Go deeper on ontamalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ontamalimab.